ASMB Assembly Biosciences Inc.

16.8
+0.1  (+1%)
Previous Close 16.7
Open 16.9
Price To Book 3.47
Market Cap 543,226,723
Shares 32,334,924
Volume 194,140
Short Ratio
Av. Daily Volume 565,821
Stock charts supplied by TradingView

NewsSee all news

  1. Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly"), today announced the closing of its previously announced underwritten public offering of 6,287,878

  2. Assembly Biosciences Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly"), today announced that it intends to offer and sell, subject to market and other conditions, shares of

  3. Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and

  4. Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and

  5. Data for Assembly Biosciences' First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019

    ABI-H0731 + nucleos(t)ide analogs (Nrtl) in patients with chronic Hepatitis B demonstrated favorable longer-term tolerability, greater reductions in HBV DNA and HBV pregenomic (pg) RNA in Phase 2 studies than Nrtl

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
VEN 307 (diltiazem cream)
Anal fissures
Phase 2a data presented at AASLD November 11, 2019.
ABI-H0731
Hepatitis B virus (HBV)
Full data due 1Q 2020.
ABI-H2158
Hepatitis B virus (HBV)
Phase 1b initiation of dosing announced June 27, 2019.
ABI-M201
Ulcerative Colitis
Phase 1a trial to be initiated 1Q 2020.
ABI-H3733
Hepatitis B virus (HBV)

Latest News

  1. Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly"), today announced the closing of its previously announced underwritten public offering of 6,287,878

  2. Assembly Biosciences Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly"), today announced that it intends to offer and sell, subject to market and other conditions, shares of

  3. Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and

  4. Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and

  5. Data for Assembly Biosciences' First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019

    ABI-H0731 + nucleos(t)ide analogs (Nrtl) in patients with chronic Hepatitis B demonstrated favorable longer-term tolerability, greater reductions in HBV DNA and HBV pregenomic (pg) RNA in Phase 2 studies than Nrtl

  6. Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and

  7. Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif.,, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and

  8. Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and